https://www.prnewswire.com/news-releases/boehringer-ingelheim-announces-first-patient-enrolled-in-phase-ii-trial-of-novel-cystic-fibrosis-treatment-balance-cf-1-300937922.html
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)
– Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat®, a handheld inhaler
